Pharmaceutical Supply – Sumatriptan Succinate Tablets

The contract involves the supply and delivery of FDA-approved Sumatriptan Succinate tablets in commercial packaging, adhering to the pharmaceutical logistics standards set by the Defense Logistics Agency. These tablets will be provided under a subcontract arrangement to meet the Department of Defense’s pharmaceutical needs, ensuring compliance with federal regulatory requirements for safety, efficacy, and quality control. The procurement is classified under NAICS code 325412, indicating the manufacturing of pharmaceutical preparations, and is intended for military and federal healthcare use. All products must be packaged in commercially approved formats while meeting DLA’s stringent logistical and traceability protocols for pharmaceutical distribution. The contract is scheduled to be active as of August 1, 2026, and will be managed under the agency’s broader supply chain framework to support medical readiness across defense installations. Delivery and fulfillment must align with DLA’s timelines, handling specifications, and quality assurance procedures, with no set-aside provisions indicated, meaning the award is open to eligible contractors regardless of business size or status.